FAS and RAS related Apoptosis defects: From autoimmunity to leukemia
暂无分享,去创建一个
[1] F. Locatelli,et al. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia , 2018, Expert review of hematology.
[2] D. Faustman,et al. Structural principles of tumor necrosis factor superfamily signaling , 2018, Science Signaling.
[3] M. Loh,et al. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia , 2017, Nature Communications.
[4] F. Rieux-Laucat,et al. Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome. , 2017, Blood advances.
[5] C. Sticht,et al. Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-κB Activation and Cell Survival , 2017, Cell reports.
[6] M. Raffeld,et al. Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. , 2017, Blood.
[7] M. Seear,et al. The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. , 2017, Clinical immunology.
[8] Matthew S. Lebo,et al. Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome , 2017, European Journal of Human Genetics.
[9] K. Chakrabandhu,et al. Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and Diseases , 2016, Front. Immunol..
[10] K. Koike,et al. Diagnosis and treatment of juvenile myelomonocytic leukemia , 2016, Pediatrics international : official journal of the Japan Pediatric Society.
[11] J. Ritz,et al. CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice , 2016, Immunity.
[12] C. Croce,et al. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment , 2016, Oncotarget.
[13] K. Schwarz,et al. Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome. , 2016, Blood.
[14] A. Baruchel,et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network , 2015, Nature Genetics.
[15] J. B. Oliveira,et al. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. , 2015, Blood.
[16] S. Miyano,et al. Somatic Mosaicism for a NRAS Mutation Associates with Disparate Clinical Features in RAS-associated Leukoproliferative Disease: a Report of Two Cases , 2015, Journal of Clinical Immunology.
[17] J. B. Oliveira,et al. Caspase-8 Deficiency Presenting as Late-Onset Multi-Organ Lymphocytic Infiltration with Granulomas in two Adult Siblings , 2015, Journal of Clinical Immunology.
[18] M. Greene,et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes , 2015, British Journal of Cancer.
[19] C. Dvorak,et al. Juvenile myelomonocytic leukemia. , 2015, Pediatric clinics of North America.
[20] A. Borkhardt,et al. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome. , 2014, Clinical immunology.
[21] C. Niemeyer. RAS diseases in children , 2014, Haematologica.
[22] T. Molina,et al. Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. , 2014, Blood.
[23] K. Schwarz,et al. Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency. , 2014, Blood.
[24] T. Tarrant,et al. Autoimmune Lymphoproliferative Syndrome: an Update and Review of the Literature , 2014, Current Allergy and Asthma Reports.
[25] F. Rieux-Laucat,et al. RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. , 2014, Blood.
[26] S. Miyano,et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia , 2013, Nature Genetics.
[27] M. Loh,et al. Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia , 2013, Leukemia.
[28] F. Rieux-Laucat,et al. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. , 2013, The Journal of allergy and clinical immunology.
[29] P. Krammer,et al. The chains of death , 2013, Cell cycle.
[30] C. Kim,et al. Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies , 2012, American journal of medical genetics. Part A.
[31] M. McDermott,et al. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases , 2012, Current opinion in rheumatology.
[32] P. Krammer,et al. Regulation of CD95/Fas signaling at the DISC , 2011, Cell Death and Differentiation.
[33] D. Steinemann,et al. Constitutional trisomy 8p11.21‐q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia , 2011, British journal of haematology.
[34] J. B. Oliveira,et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. , 2011, Blood.
[35] T. Morio,et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. , 2011, Blood.
[36] H. Fuchs,et al. Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain. , 2011, Blood.
[37] F. Rieux-Laucat,et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. , 2011, The Journal of clinical investigation.
[38] F. Rieux-Laucat,et al. Whole-exome-sequencing-based discovery of human FADD deficiency. , 2010, American journal of human genetics.
[39] F. Rieux-Laucat,et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. , 2010, Blood.
[40] J. B. Oliveira,et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. , 2010, Blood.
[41] M. V. D. van den Heuvel-Eibrink,et al. Molecular basis of juvenile myelomonocytic leukemia , 2010, Haematologica.
[42] H. Hasle. Malignant Diseases in Noonan Syndrome and Related Disorders , 2009, Hormone Research in Paediatrics.
[43] F. Rieux-Laucat,et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. , 2009, Blood.
[44] M. Loh,et al. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. , 2009, Leukemia research.
[45] F. Rieux-Laucat,et al. Human TCR α/β+ CD4−CD8− Double-Negative T Cells in Patients with Autoimmune Lymphoproliferative Syndrome Express Restricted Vβ TCR Diversity and Are Clonally Related to CD8+ T Cells1 , 2008, The Journal of Immunology.
[46] M. Willingham,et al. Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. , 2008, Immunity.
[47] A. Strasser,et al. Apoptosis Regulators Fas and Bim Cooperate in Shutdown of Chronic Immune Responses and Prevention of Autoimmunity , 2008, Immunity.
[48] L. Davis,et al. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. , 2008, Immunity.
[49] M. Ferretti,et al. Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome , 2007, BMC Immunology.
[50] J. Puck,et al. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib , 2007, BMC Medical Genetics.
[51] Inna N. Lavrik,et al. Life and death in peripheral T cells , 2007, Nature Reviews Immunology.
[52] K. Koike,et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. , 2007, Blood.
[53] Peter J. Munson,et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome , 2007, Proceedings of the National Academy of Sciences.
[54] A. Anel,et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. , 2006, Blood.
[55] A. Schäffer,et al. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome , 2006, Human Genetics.
[56] L. Salmena,et al. Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder , 2005, The Journal of experimental medicine.
[57] Lucio Luzzatto,et al. A quantitative measurement of the human somatic mutation rate. , 2005, Cancer research.
[58] F. Rieux-Laucat,et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. , 2004, The New England journal of medicine.
[59] C. Babinet,et al. Complete Loss of Fas Ligand Gene Causes Massive Lymphoproliferation and Early Death, Indicating a Residual Activity of gld Allele 1 , 2004, The Journal of Immunology.
[60] J. Puck,et al. Immune disorders caused by defects in the caspase cascade , 2003, Current allergy and asthma reports.
[61] Peter Guttorp,et al. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. , 2002, Blood.
[62] F. Rieux-Laucat,et al. Inactivation of the Fas gene by Alu insertion: retrotransposition in an intron causing splicing variation and autoimmune lymphoproliferative syndrome , 2002, Genes and Immunity.
[63] J. Puck,et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency , 2002, Nature.
[64] C. Mohan,et al. Genetic Dissection of SLE , 2002, The Journal of experimental medicine.
[65] F. Rieux-Laucat,et al. Differential sensitivity of Jurkat and primary T cells to caspase‐independent cell death triggered upon Fas stimulation , 2002, European journal of immunology.
[66] Brian Seed,et al. Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase RIP as effector molecule , 2000, Nature Immunology.
[67] F. Martinon,et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways , 2000, Current Biology.
[68] A. Strasser,et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.
[69] E. Mantadakis,et al. Prevalence of priapism in children and adolescents with sickle cell anemia. , 1999, Journal of pediatric hematology/oncology.
[70] J. Puck,et al. Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II , 1999, Cell.
[71] N. Kabra,et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1 , 1998, Nature.
[72] D. Kono,et al. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. , 1998, The Journal of clinical investigation.
[73] T. Miyawaki,et al. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. , 1998, International immunology.
[74] Pamela J. Fink,et al. Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand , 1998, The Journal of experimental medicine.
[75] B. Bader-Meunier,et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. , 1997, The Journal of pediatrics.
[76] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.
[77] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .
[78] L. Notarangelo,et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. , 1997, Blood.
[79] F. Rieux-Laucat,et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions , 1996, The Lancet.
[80] P. Schur,et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. , 1996, The Journal of clinical investigation.
[81] N. Yoshida,et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[82] D. Bellgrau,et al. A role for CD95 ligand in preventing graft rejection , 1995, Nature.
[83] Warren Strober,et al. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.
[84] F. Rieux-Laucat,et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.
[85] E. Lacy,et al. Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome , 1995, The Journal of experimental medicine.
[86] F. Ramsdell,et al. Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.
[87] N. Copeland,et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.
[88] H. Ikeda,et al. A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse , 1990, The Journal of experimental medicine.
[89] P. Möller,et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.
[90] S. Yonehara,et al. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.
[91] F. Takei. Unique surface phenotype of T cells in lymphoproliferative autoimmune MRL/Mp-lpr/lpr mice. , 1984, Journal of Immunology.
[92] A. Theofilopoulos,et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains , 1978, The Journal of experimental medicine.
[93] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[94] R. Lockshin,et al. PROGRAMMED CELL DEATH--I. CYTOLOGY OF DEGENERATION IN THE INTERSEGMENTAL MUSCLES OF THE PERNYI SILKMOTH. , 1965, Journal of insect physiology.
[95] L. Notarangelo,et al. Autoimmune lymphoproliferative syndrome caused by a homozygous FasL mutation that disrupts FasL assembly. , 2016, The Journal of allergy and clinical immunology.
[96] E. Paz-Artal,et al. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation. , 2016, Immunobiology.
[97] Jb Oliveira,et al. NRAS mutation causes a human autoimmune lymphopro-liferative disease , 2007 .
[98] A. Chiocchetti,et al. The broad spectrum of autoimmune lymphoproliferative disease: molecular bases, clinical features and long-term follow-up in 31 patients. , 2006, Haematologica.
[99] A. Langerak,et al. Autoimmune Lymphoproliferative Syndrome (ALPS) in a Child from Consanguineous Parents: A Dominant or Recessive Disease? , 2000, Pediatric Research.
[100] D. Chitayat,et al. Juvenile myelomonocytic leukemia and Noonan syndrome. , 1999, Journal of pediatric hematology/oncology.
[101] S. Nagata,et al. Fas and Fas ligand: lpr and gld mutations. , 1995, Immunology today.